E-resources
PDF-
DiNardo, Courtney D; Jonas, Brian A; Pullarkat, Vinod; Thirman, Michael J; Garcia, Jacqueline S; Wei, Andrew H; Konopleva, Marina; Döhner, Hartmut; Letai, Anthony; Fenaux, Pierre; Koller, Elizabeth; Havelange, Violaine; Leber, Brian; Esteve, Jordi; Wang, Jianxiang; Pejsa, Vlatko; Hájek, Roman; Porkka, Kimmo; Illés, Árpád; Lavie, David; Lemoli, Roberto M; Yamamoto, Kazuhito; Yoon, Sung-Soo; Jang, Jun-Ho; Yeh, Su-Peng; Turgut, Mehmet; Hong, Wan-Jen; Zhou, Ying; Potluri, Jalaja; Pratz, Keith W
The New England journal of medicine, 08/2020, Volume: 383, Issue: 7Journal Article
In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3) and the median overall survival was longer (14.7 vs. 9.6 months) among patients who received azacitidine plus venetoclax (a B-cell lymphoma 2 antagonist) than among those who received azacitidine alone.
